January 12, 1999
NAME
PURE HEALTH PRODUCTS
PRIVATE LIMITED
REGISTERED OFFICE
128/2 Swarup Nagari, Karve
Road, Kothrud, Pune – 411 029, Maharashtra, India
Tel. No. 91-20-332 537
Fax No. 91-20-362 036
BRANCH
Off B. S. Road, Dadar, Mumbai – 400 028, India.
MAJOR SHAREHOLDERS
|
Name of Shareholder |
No. of Shares |
|
|
|
|
Mr. Ramakant K. Sapte |
49,000 |
|
Mr. Ajit S. Belwalkar |
31,500 |
|
Mr. Sameer S. Belwalkar |
11,500 |
|
Mr. Dnyaneshwar Agashe |
45,850 |
BUSINESS
The company is engaged in manufacturing and marketing of Pharmaceutical and Dental Materials.
The company is trade terms with :
K S. P. B. (Inc), 179/2 Garmal, Vadgaon Dhayal, Pune – 411 041, Maharashtra, India
K Maneesh Pharmaceuticals Private Limited, Plot No. 43, Ancillary Industrial Estate, Govandi, Mumbai – 400 043, India
K Alphadental Products Company, 1920, N. Clybom Ave., Chicago, IL 60694, U.S.A.
K Associated Dental Products Limited, Purton, Swindon Wiltshire SN5 9HT, U.K.
K DMG Hamburg, Elbgaustrabe 248, 22547 Hamburg, Germany
The company operates from a caption owned office premises and employs 270 persons as on 31st March, 1998.
FINANCIAL INFORMATION
The company’s latest financial information for the period ended 31st March, 1998 is enclosed herewith.
****************************
ABRIDGED BALANCE SHEET AS ON
31ST March, 1998
[figures are in Rupees Millions]
|
LIABILITIES |
31.03.1998 |
ASSETS |
31.03.1998 |
|
|
|
|
|
|
Share Capital |
1.545 |
Fixed Assets |
2.304 |
|
Reserves & Surplus |
0.246 |
Investments |
0.010 |
|
Secured Loans |
2.102 |
Inventories |
3.920 |
|
Unsecured Loans |
5.322 |
Sundry Debtors |
18.992 |
|
Current Liabilities |
17.291 |
Cash & Bank Balances |
1.032 |
|
Provisions |
2.473 |
Other Current Assets |
0.563 |
|
|
|
Loans & Advances |
2.157 |
|
|
|
Misc. Expenses |
0.001 |
|
|
|
|
|
|
GRAND TOTAL |
28.979 |
GRAND TOTAL |
28.979 |
IMPORTANT FINANCIAL
INFORMATION FOR LAST TWO PERIODS
[figures are in Rupees Millions]
|
PARTICULARS |
31.03.1998 |
31.03.1997 |
|
Sales Turnover [including other income] |
80.078 |
67.681 |
|
|
|
|
|
Profit/(Loss) Before Tax |
0.299 |
0.079 |
|
Provision for Taxation |
0.075 |
0.057 |
|
Profit/(Loss) After Tax |
0.224 |
0.022 |
Attachment 1
|
Report Update On |
23rd December, 1998 |
|
|
|
|
Report on |
pure health products private
limited |
|
|
|
|
Registered Office |
128/2 Swarup Nagari, Karve
Road, Kothrud, Pune – 411 029, Maharashtra, India |
|
|
|
|
Tel. No. |
91-212-332 537 / 360 036 |
|
Fax No. |
-- |
|
E-Mail |
-- |
|
Telex |
-- |
Attachment 2
S U M M A R Y
|
Incorporated |
1988 |
Status |
Satisfactory |
|
|
|
|
|
|
Registration No. |
47757 |
Chief Executive |
Ramakant Sapte |
|
|
|
|
|
|
Capital (Rs.) |
1.545 millions |
Payments |
Usually Correct |
|
|
|
|
|
|
Sales (Rs.) |
67.556 millions |
Litigation |
No Information |
|
|
|
|
|
|
Net Worth (Rs.) |
1.456 millions |
Banking Reputation |
Satisfactory |
|
|
|
|
|
|
No. of Employees |
200 |
Auditors |
S. M. Suratwala & Company |
|
|
|
|
|
|
Credit Rating |
Ba (See attachment 3) |
||
INDUSTRY
Production value of Bulk Drugs and Formulations has grown at 20% and 15% respectively over the last two years. The annual per capita expenditure on drugs continues to be much lower than that in developed countries despite the government's attempts to ensure the availability of essential drugs at affordable prices through price regulations by way of the Drug Price Control Order (DPCO). Presently, the DPCO, 1995 regulates the price of 73 drugs.
The structure and dynamics of the Indian Pharma Industry are unique primarily on account of the process patent regime, price controls and exemptions to SSIs. In the developed countries that recognise product patents, R & D Capabilities, ability to develop and launch new products have been the bases for competition. The Indian Patents Act, 1970 (IPA), which recognises process patents, has made it possible for Indian Manufacturers to produce internationally patented drugs by developing an alternate manufacturing process. As a signatory to the World Trade Organisation (WTO), India has agreed to improve legislative protection to Trade Related Intellectual Property Rights (TRIPS) which recognises only product patents.
********************
BRANCH
Nil
HISTORY
The company was incorporated on 21st June, 1988 having Company Registration Number 47757.
LEGAL FORM
It is a Private Limited Liability company.
DIRECTORS
|
Mr. Ramakant K. Sapte |
Chairman |
|
Mr. Ajit S. Belwalkar |
Director |
|
Mr. Sameer S. Belwalkar |
Director |
BUSINESS
The company is engaged in marketing of pharmaceutical products such as Liquids (Orals), Tablets & Capsules, Creams & Grannuals and Injections.
The management in its annual report for the period ended 31st March, 1997 states that during the ninth year of operation the company has achieved the turnover of Rs.67.6 millions. The profit for the year amounted to Rs.0.078 millions after providing Rs.0.358 millions for depreciation. The company consolidated its marketing network further in various states like Maharashtra, Andhra Pradesh, Madhya Pradesh, Orissa, Kerala, Gujarat, Punjab and Jammu & Kashmir.
The company does not have any foreign exchange transactions. All of the company’s trading activities are carried on inside the borders of India.
The company’s fixed assets of important value includes Land & Building, Plant & Machinery, Electric Installations, Vehicles, Computers, Office Equipments, Electric Equipments and Furniture & Fixtures.
ASSOCIATE CONCERNS
K Vasudha Pharmaceuticals Inc
BANKERS
K Union Bank of India, Karve Road Branch, Pune – 411 004, Maharashtra, India
FINANCIAL INFORMATION
The company’s last available financial information for the period ended 31st March, 1997 is enclosed herewith.
CAPITAL STRUCTURE
|
Authorised Capital : |
||
|
250,000 |
Equity Shares of Rs.10/- each |
Rs.2.500 millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital : |
||
|
154,520 |
Equity Shares of Rs.10/- each |
Rs.1.545 millions |
COMMENTS
Subject is a well-established and reputed company, controlled and financed by Belwalkar Family. Their trade relations are reported as fair. General financial position is satisfactory.
The company can be considered normal for business dealings at usual trade terms and conditions.
ABRIDGED BALANCE SHEET AS ON
31ST March, 1997
[figures are in Rupees Millions]
|
SOURCES OF FUNDS |
|
31.03.1997 |
31.03.1996 |
|
|
|
|
|
|
SHAREHOLDERS’ FUNDS |
|
|
|
|
1] Share Capital |
|
1.545 |
1.545 |
|
2] Reserves & Surplus |
|
0.000 |
0.000 |
|
|
|
|
|
|
LOAN FUNDS |
|
|
|
|
1] Secured Loans |
|
1.296 |
1.963 |
|
2] Unsecured Loans |
|
2.972 |
2.688 |
|
|
|
|
|
|
GRAND TOTAL |
|
5.813 |
6.196 |
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
|
1.892 |
2.017 |
|
|
|
|
|
|
INVESTMENTS |
|
0.944 |
0.451 |
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
Inventories |
|
3.299 |
2.024 |
|
Sundry Debtors |
|
12.606 |
12.780 |
|
Cash & Balances |
|
1.263 |
0.617 |
|
Loans & Advances |
|
0.935 |
0.560 |
|
Total Current
Assets |
|
18.103 |
15.981 |
|
Less : |
|
|
|
|
Current Liabilities |
|
13.125 |
10.291 |
|
Provisions |
|
2.095 |
2.076 |
|
Net Current
Assets |
|
2.883 |
3.614 |
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
|
0.002 |
0.003 |
|
|
|
|
|
|
PROFIT & LOSS ACCOUNT |
|
0.089 |
0.111 |
|
|
|
|
|
|
GRAND TOTAL |
|
5.813 |
6.196 |
IMPORTANT FINANCIAL
INFORMATION FOR TWO PERIODS
[figures are in Rupees Millions]
|
PARTICULARS |
|
31.03.1997 |
31.03.1996 |
|
|
|
|
|
|
Sales Turnover [including other income] |
|
67.681 |
65.221 |
|
|
|
|
|
|
Profit/(Loss) Before Tax |
|
0.078 |
0.153 |
|
Provision for Taxation |
|
0.056 |
0.070 |
|
Profit/(Loss) After Tax |
|
0.022 |
0.083 |
|
|
|
|
|
|
Dividend |
|
0.000 |
0.000 |
|
|
|
|
|
|
Expenditures : |
|
|
|
|
Cost of Goods Sold |
|
33.637 |
32.487 |
|
Employment |
|
16.639 |
14.676 |
|
Administrative & Office Expenses |
|
2.661 |
2.244 |
|
Selling & Distribution Expenses |
|
13.435 |
14.552 |
|
Financial Costs |
|
0.874 |
0.740 |
|
Depreciation |
|
0.357 |
0.368 |
|
Preliminary Expenses Written-off |
|
0.001 |
0.001 |
|
Provision for Taxation |
|
0.057 |
0.070 |
|
Balance C/d |
|
0.020 |
0.083 |
|
Total Expenditures |
|
67.681 |
65.221 |
Attachment 3
|
SCORE SHEET |
|
SCORE |
CREDIT RATING |
STATUS |
PROPOSED CREDIT LINE |
|
>86 |
Aaa |
Possesses an extremely sound financial base with the
strongest capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed
for credit transaction. It has above average (strong) capability for payment
of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded
healthy. General unfavourable factors will not cause fatal effect. Satisfactory
capability for payment of interest and principal sums |
Fairly
Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to
meet normal commitments. Maybe drawn to slightly difficult position as unfavourable
conditions arise. Minimal assurance for timely payment on interest and
principal sums |
Moderate |
|
26-40 |
B |
Unfavourable & favourable factors carry similar
weight in credit consideration. Capability to overcome financial difficulties
seems comparatively limited or considered not known. Capability to pay both
interest and principal sums is doubtful |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and
principal sums in default or expected to be in default upon maturity |
Limited
with full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be
exercised |
Credit
not recommended |